ESR1 mutations have emerged as a key mechanism of resistance to endocrine therapy in patients with ER-positive metastatic breast cancer [24] and their detection is now considered to be highly promising as a prognostic and predictive biomarker in this type of cancer [24,25]. The gene discussed is ESR1; the disease is cancer.